Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Ligand Avinza Co-promotion Deal Adds 700 Reps; Goal Is 10% Share By 2008

  • News

Executive Summary

Ligand's Avinza co-promotion agreement with Organon adds more than 700 reps to detail the extended-release morphine product

You may also be interested in...



Akzo Nobel Pharma “Rough Ride” In 2004 Offset By Partnering, R&D Potential

Akzo Nobel hopes that partnering agreements and investment in R&D will help its pharmaceutical division weather the "rough ride" expected in 2004

Akzo Nobel Pharma “Rough Ride” In 2004 Offset By Partnering, R&D Potential

Akzo Nobel hopes that partnering agreements and investment in R&D will help its pharmaceutical division weather the "rough ride" expected in 2004

Teva’s Generic Remeron Exclusivity Cut To Five Months By FDA Rules

Teva's generic Remeron (mirtazapine) will have only five months of marketing exclusivity from its approval date due to FDA's current interpretation of the trigger for first-to-file 180-day marketing exclusivity under the Waxman/Hatch Act, Teva reported in its Feb. 18 earnings teleconference

Table

View full table

Tags:
UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By